BioXcel Therapeutics Inc
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. I… Read more
Market Cap & Net Worth: BioXcel Therapeutics Inc (BTAI)
BioXcel Therapeutics Inc (NASDAQ:BTAI) has a market capitalization of $36.08 Million ($36.08 Million) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #23295 globally and #8154 in its home market, demonstrating a 6.45% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BioXcel Therapeutics Inc's stock price $1.65 by its total outstanding shares 21869491 (21.87 Million).
BioXcel Therapeutics Inc Market Cap History: 2018 to 2026
BioXcel Therapeutics Inc's market capitalization history from 2018 to 2026. Data shows change from $84.42 Million to $36.08 Million (-21.06% CAGR).
Index Memberships
BioXcel Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.20 Trillion | 0.00% | #620 of 976 |
|
NASDAQ Composite
IXIC
|
$32.97 Trillion | 0.00% | #2044 of 3165 |
Weight: BioXcel Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
BioXcel Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BioXcel Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
3.61x
BioXcel Therapeutics Inc's market cap is 3.61 times its annual revenue
1.00x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $1.01 Billion | $24.30 | -$82.01 Million | 41579032.27x | N/A |
| 2022 | $469.76 Million | $375.00K | -$165.76 Million | 1252.68x | N/A |
| 2023 | $64.51 Million | $1.38 Million | -$179.05 Million | 46.75x | N/A |
| 2024 | $8.18 Million | $2.27 Million | -$59.60 Million | 3.61x | N/A |
Competitor Companies of BTAI by Market Capitalization
Companies near BioXcel Therapeutics Inc in the global market cap rankings as of March 19, 2026.
Key companies related to BioXcel Therapeutics Inc by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #422 globally with a market cap of $51.61 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #432 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #452 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #422 | Zoetis Inc | NYSE:ZTS | $51.61 Billion | $117.35 |
| #432 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.31 |
| #452 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
BioXcel Therapeutics Inc Historical Marketcap From 2018 to 2026
Between 2018 and today, BioXcel Therapeutics Inc's market cap moved from $84.42 Million to $ 36.08 Million, with a yearly change of -21.06%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $36.08 Million | +3.12% |
| 2025 | $34.99 Million | +327.92% |
| 2024 | $8.18 Million | -87.33% |
| 2023 | $64.51 Million | -86.27% |
| 2022 | $469.76 Million | +5.66% |
| 2021 | $444.61 Million | -56.00% |
| 2020 | $1.01 Billion | +216.22% |
| 2019 | $319.51 Million | +278.50% |
| 2018 | $84.42 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of BioXcel Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $36.08 Million USD |
| MoneyControl | $36.08 Million USD |
| MarketWatch | $36.08 Million USD |
| marketcap.company | $36.08 Million USD |
| Reuters | $36.08 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.